Cochrane · systematic review · CD015219
Favipiravir for treating COVID‐19
Korula, P, Alexander, H, John, JSara, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 42.9%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Favipiravir versus no treatment, supportive treatment, or other antiviral treatment for treating COVID‐19
Population: people with confirmed COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality – at 28 to 30 days, or in‐hospital Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 0.84 [0.49, 1.46] | 11 studies · 3459 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Progression to invasive mechanical ventilation Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 0.86 [0.68, 1.09] | 8 studies · 1383 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Need for admission to hospital (if ambulatory) Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 1.04 [0.44, 2.46] | 4 studies · 670 participants | Low Downgraded: imprecision, inconsistency |
Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | HR 1.13 [0.69, 1.83] | 4 studies · 721 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Progression to oxygen therapy Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 1.2 [0.83, 1.75] | 2 studies · 543 participants | Low Downgraded: imprecision, inconsistency |
All adverse events Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 1.27 [1.05, 1.54] | 18 studies · 4699 participants | Low Downgraded: imprecision, inconsistency |
Serious adverse events attributable to the drug Favipiravir vs no treatment, supportive treatment, or other antiviral treatment | RR 1.04 [0.76, 1.42] | 12 studies · 3317 participants | Low Downgraded: risk of bias, imprecision, inconsistency |